Positions
- Assistant Professor
-
Medicine - Hematology & Oncology
Dan L Duncan Comprehensive Cancer Center
ÌÇÐÄÊÓƵ of Medicine
Houston, Texas, United States
GI medical Oncology
Addresses
- O'Quinn Medical Tower at Baylor St. Luke's Medical Center's McNair Campus (Office)
-
Dan L Duncan Comprehensive Cancer Center
1919 Old Spanish Trail
Houston, TX, 77054
United States
Phone: (832) 957-6500
Fax: (713) 610-4596
Tannaz.Armaghany@bcm.edu
Education
- MD from Tabriz University
- 11/1996 - Tabriz, Iran
- Residency at Cook County Hospital
- 08/2005 - chicago, Illinois, United States
- Fellowship at Louisiana State University Health
- 07/2010 - Shreveport, Louisiana, United States
- Hematology and Medical Oncology
- Fellowship at Arizona State University
- 08/2011 - Tucson, Arizona, United States
- Integrative Medicine
Certifications
- Medical Oncology Board certification
- ABIM
- Hematology Board certification
- ABIM
- Internal Medicine Board certification
- ABIM
Professional Interests
- Gastrointestinal Medical Oncology
- Neuroendocrine Tumors
- Hepatocellular Carcinoma and hepatobillary cancers
Projects
- OPTIM trial
- ÌÇÐÄÊÓƵ of Medicine- Dan Duncan Comprehensive cancer center
- A WINDOW OF OPPORTUNITY TRIAL WITH MECLIZINE IN HEPATOCELLULAR CARCINOMA Primary Investigator
- (GLYCAR STUDY) GPC3-CAR T cells for patients with hepatocellular carcinoma
- ÌÇÐÄÊÓƵ of Medicine- Dan Duncan Comprehensive cancer center
- Primary Investigator
- TACTOPS
- ÌÇÐÄÊÓƵ of Medicine- Dan Duncan Comprehensive cancer center
- Tumor-Associated Antigen (TAA)-Specific Cytotoxic T Lymphocytes Administered in Patients With Pancreatic Chancer. Co-investigator
- S1815: A PHASE III RANDOMIZED TRIAL OF GEMCITABINE, CISPLATIN, AND NAB-PACLITAXEL VERSUS GEMCITABINE AND CISPLATIN IN NEWLY DIAGNOSED, ADVANCED BILIARY TRACT CANCERS
- ÌÇÐÄÊÓƵ of Medicine- Dan Duncan Comprehensive cancer center
- Co-PI
- GABLE: A PILOT STUDY IN GASTRIC CANCER OF ASSIGNMENT TO POSTOPERATIVE CHEMORADIATION OR CHEMOTHERAPY BASED UPON SURGICAL LYMPH NODE ASSESSMENT AFTER PREOPERATIVE CHEMOTHERAPY, WITH GENE ASSAY AS CORRELATE OF BIOLOGIC RESPONSE
- Primary Investigator
- QED: A PHASE 3 MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF ORAL INFIGRATINIB VERSUS GEM)CITABINE WITH CISPLATIN IN SUBJECTS WITH ADVANCED/METASTATIC OR INOPERABLE CHOLANGIOCARCINOMA WITH FGFR2 GENE FUSIONS/TRANSLOCATIONS: THE PROOF TRIAL
- Co-PI
Memberships
- American College of Clinical Oncology
- (07/2007)
- Amerian Society of hematology
- (07/2007)
- North American Neuroendocrine Tumor Society
- SWOG member
- (07/2010)
- Harris county Medical Society
- (08/2013)
- Iranian American Medical Association
- President IAMA-Texas branch
- Dan L Duncan Comprehensive Cancer Center
- Member
- International Society of Liver cancer
- Associate Member
- Texas Medical Association
to edit your profile